Four brands of Binnopharm Group win the Product of the Year 2022 award
30.11.2022
The ceremony brought together top Russian consumer brands and celebrities for the 24th installment of Russia’s well-known annual national award to celebrate top-selling consumer goods.
Maxilac won the Consumer Confidence and Choice nomination in the category of dietary supplements for gastrointestinal microflora restoration. It is produced by European companies, Danisco and Labomar, in accordance with GMP and ISO 9001 standards and supplied to Russia as a finished product. Binnopharm Group owns the Maxilac brand and sells products in Russia and the CIS.
Neobutin won the Soaring Sales Growth and Customer Care nomination in the category of gastrointestinal antispasmodics. This was a landmark victory for Binnopharm Group, having met the annual sales target well before the end of the year. Neobutin also hit a milestone with its total sales exceeding RUB 1 bn.
Kagocel is the only antiviral agent in Russia which won three awards in 2022, namely the Green Cross, Russian Pharma Awards, and the Product of the Year. The medicine boasts unique properties allowing for both treatment of ARVI and influenza at the first stroke of disease and late treatment up to the fourth day from disease onset. Kagocel has won numerous national pharmaceutical awards, including the National Pharmaceutical Rating and Smart Pharma Awards.
Venarus picked up the Venotonic nomination.
Rustem Muratov, Binnopharm Group’s CEO: “We are happy to see our products become the nation’s favourites. Four nominations for the Product of the Year 2022 award reinforce the high standards of quality and the great trust of Russian consumers.”
According to experts, a company winning the Product of the Year award is set to increase sales by an average of 30% compared to other products in its category. 54% of consumers tend to trust a product labelled as the Product of the Year.
Maxilac won the Consumer Confidence and Choice nomination in the category of dietary supplements for gastrointestinal microflora restoration. It is produced by European companies, Danisco and Labomar, in accordance with GMP and ISO 9001 standards and supplied to Russia as a finished product. Binnopharm Group owns the Maxilac brand and sells products in Russia and the CIS.
Neobutin won the Soaring Sales Growth and Customer Care nomination in the category of gastrointestinal antispasmodics. This was a landmark victory for Binnopharm Group, having met the annual sales target well before the end of the year. Neobutin also hit a milestone with its total sales exceeding RUB 1 bn.
Kagocel is the only antiviral agent in Russia which won three awards in 2022, namely the Green Cross, Russian Pharma Awards, and the Product of the Year. The medicine boasts unique properties allowing for both treatment of ARVI and influenza at the first stroke of disease and late treatment up to the fourth day from disease onset. Kagocel has won numerous national pharmaceutical awards, including the National Pharmaceutical Rating and Smart Pharma Awards.
Venarus picked up the Venotonic nomination.
Rustem Muratov, Binnopharm Group’s CEO: “We are happy to see our products become the nation’s favourites. Four nominations for the Product of the Year 2022 award reinforce the high standards of quality and the great trust of Russian consumers.”
According to experts, a company winning the Product of the Year award is set to increase sales by an average of 30% compared to other products in its category. 54% of consumers tend to trust a product labelled as the Product of the Year.
